Perivascular mesenchymal precursor cells
View Patent ↗Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1 bri . The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.
1. A population of cells enriched for 3G5 cells, wherein such 3G5 cells are mesenchymal precursor cells which comprise mesenchymal precursor cells capable of giving rise to colony forming unit-fibroblast (CFU-F), and wherein at least 30% of the total cells of the population are positive for the marker 3G5.
2. The enriched population of claim 1 wherein the MPCs are enriched from a perivascular niche within a non-haemopoietic vascularised tissue.
3. The enriched population of claim 1 wherein the MPCs are enriched from a tissue of the group consisting of skin, liver, kidney, heart, adipose tissue, teeth, dental pulp, retina, brain, hair follicles, intestine, lung, spleen, lymph node, thymus, pancreas, bone, ligament, bone marrow, tendon and skeletal muscle.
4. The enriched population of claim 1 wherein the MPCs are also positive for one or more of the perivascular cell markers MUC18/CD146 and alpha-smooth muscle actin.
5. The enriched population of claim 1 wherein the enriched population comprises at least 0.1% STRO-1 bri MPCs.
6. The enriched population of claim 1 wherein the enriched population comprises at least 1% STRO-1 bri MPCs.
7. The enriched population of claim 1 wherein the MPCs are positive for the markers STRO-1 bri , MUC18/CD146, and alpha-smooth muscle actin.
8. The enriched population of claim 1 wherein the MPCs are positive for one or more markers selected from the group consisting of THY-1, VCAM-1, ICAM-1, PECAM-1, CD49a/CD49b/CD29, CD49c/CD29, CD49d/CD29, CD29, CD61, integrin beta 5, 6-19, thrombomodulin, CD10, CD13, SCF, STRO-1 bri , PDGF-R, EGF-R, IGF1-R, NGF-R, FGF-R and Leptin-R (STRO-2).
9. The enriched population of claim 1 wherein the MPCs are negative for the haemopoietic markers CD45, CD34, and glycophorin A.
10. The enriched population of claim 1 wherein the MPCs have the capacity to be induced to differentiate to form progeny cells comprising one or more of at least osteoblast, odontoblast, dentin-producing, chondrocyte, tendon, ligament, cartilage, adipocyte, fibroblast, marrow stroma, osteoclast- and hematopoietic-supportive stroma, cardiac muscle, smooth muscle, skeletal muscle, pericyte, vascular, epithelial, glial, neuronal, astrocyte or oligodendrocyte cell type.
11. An enriched population of claim 1 comprising at least 0.1% MPCs capable of forming a clonogenic colony.
12. An enriched population of claim 1 comprising at least 1% MPCs capable of forming a clonogenic colony.